{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:25:50Z","timestamp":1789691150667,"version":"4.0.1"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Hidradenitis suppurativa is a complex, chronic, difficult to treat condition belonging to the spectrum of cutaneous immune-mediated inflammatory diseases. Systemic treatment options for moderate-severe disease are limited to TNF-alpha antagonists and other biologic agents, with limited clinical evidence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report two adult patients with severe hidradenitis suppurativa presenting concomitant psoriatic arthritis and multiple medical comorbidities. Both were ineligible or resistant to adalimumab, the only biologic drug approved for the treatment of hidradenitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Both patients were diagnosed with severe Hurley III-stage disease and psoriatic arthritis, showing resistance to first-line systemic treatments and a complex comorbidity profile.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Patients underwent treatment with apremilast, an oral phosphodiesterase-4 inhibitor, approved for the treatment of psoriatic arthritis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 16 weeks of treatment, a clinically relevant improvement of inflammatory lesions, skin- and arthritis-related pain, and patient-reported outcomes was achieved in both patients. Apremilast was well tolerated and continued up to 48 weeks of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>We report the \u201creal-life\u201d use of apremilast in the treatment of multimorbid patients with hidradenitis suppurativa and review its potential role in the management of this severe condition.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000018991","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T02:31:13Z","timestamp":1580351473000},"page":"e18991","source":"Crossref","is-referenced-by-count":16,"title":["Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients"],"prefix":"10.1097","volume":"99","author":[{"given":"Simone","family":"Garcovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Giovanardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalma","family":"Malvaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,1]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11154-016-9328-5","article-title":"Evidence-based approach to the treatment of hidradenitis suppurativa\/acne inversa, based on the European guidelines for hidradenitis suppurativa","volume":"17","author":"Gulliver","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-017-0709-1","article-title":"Apremilast: a review in psoriasis and psoriatic arthritis","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R4-20230915","first-page":"170","article-title":"Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 study","volume":"18","author":"Kerdel","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jaad.2017.02.026","article-title":"Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients","volume":"76","author":"Weber","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R6-20230915","article-title":"Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers","author":"Vossen","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R7-20230915","first-page":"1","article-title":"Off-label studies on apremilast in dermatology: a review","author":"Maloney","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/14712598.2018.1504016","article-title":"An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly","volume":"18","author":"Di Lernia","year":"2018","journal-title":"Expert Opin Biol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:30:33Z","timestamp":1694813433000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018991"}},"subtitle":["Case report and review of literature"],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":8,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000018991","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}